Keywords:
Genital / Reproductive system male, Pelvis, MR, MR-Diffusion/Perfusion, MR-Spectroscopy, Observer performance, Outcomes analysis, Structured reporting, Cancer
Authors:
D. Gutierrez, O. Chirife, C. Pineda; Barcelona/ES
DOI:
10.1594/ecr2013/C-0968
Purpose
Multiparametric MRI (mpMRI) provides a noninvasive approach to the characterization of prostate anatomy,
angiogenesis,
cell density and metabolism (T2 weighted image (T2w),
dynamic contrast enhance (DCE) sequences and diffusion weighted image (DWI) and spectroscopy respectively) not just for local staging,
but also for the initial diagnosis of prostatic carcinoma [2],
having emerged as a new and important tool in the field.
Even though there is supportive evidence for the use of mpMRI,
the lack of standardization of diagnostic criteria has stalled the wide application of this tool.
This issue has been addressed as of 2012 by the European Society of Urogenital Radiology (ESUR) with the publication of a unified scoring system for the mpMRI,
known as the Magnetic Resonance Prostate Imaging Reporting and Data System (MR PI-RADS) in an effort to emulate similar systems like the one used by breast radiologists (BI-RADS),
in order to reduce the interobserver variability while increasing the diagnostic value of the technique [3,
4,
5].
The PI-RADS is currently being validated in several studies,
such as the multicentric prospective study from Daniel Portalez et al [3],
showing promising results.
The purpose of our study is to evaluate the role of prostate mpMRI using the PI-RADS system in patients with biochemical suspicion of prostatic cancer and at least one previous negative biopsy using the subsequent targeted biopsy as gold standard.
Evaluating:
- The interobserver reliability
- The relationship between PI-RADS scores and histological results